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OBJECTIVES: Ivabradine prevents myocardial ischemia by decreasing heart rate in
stable angina pectoris (SAP) patients. This analysis presents the cost-effectiveness
analysis of ivabradine in the treatment of SAP.METHODS: AMarkov-chain model,
in which, patients with SAP treated with ivabradine and comparators are followed
for twenty years, was built. Annual rates of revascularization, other cardiovascular
events and mortality were calculated. Direct costs were taken into account from
the perspective of social security institution. Randomized clinical studies, other
comparative studies andmeta-analysis were taken as sources of inputs. RESULTS:
Annual revascularization rate was 5.0% for ivabradine and 6.5-7.0% for compara-
tors. Estimated number of revascularizations within 20 years was 120 procedures
per 100 patients with ivabradine as compared to 135-139 with others. Annual car-
diovascular event rate was 7.5% for ivabradine and 10.4-10.9% for comparators.
Total number of cardiovascular events within 20 years was 151 events per 100
patients with ivabradine as compared to 207-219 with others. Duration of event-
free life years was 9.9 years with ivabradine and 7.7-8.1 years with others. Incre-
mental Cost Effectiveness Ratio for ivabradine decreased down to cost-effective-
ness threshold (three times GDP per capita per one event-free life year) within the
first year versus isosorbide mononitrate and verapamil, and in the second year
versus amlodipine and diltiazem. Annual mortality rate was 1.7% with ivabradine,
while it was 2.2%with comparators. Life-years gained per 20 years with ivabradine
was 0.8 years (16.4 vs 15.7 with ivabradine and with comparators, respectively).
CONCLUSIONS:When savings provided by the decreases in revascularization and
cardiovascular event rates are taken into account, annual treatment cost differ-
ence between ivabradine and other drugs decreases. Longer life years and event-
free life years provided by ivabradine makes it a cost effective choice for SAP.
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OBJECTIVES: The main objective of this study was to evaluate the cost effective-
ness of the managed care in the case of heart failure. Also, the proportion of pa-
tients with a hospital free year was compared using managed care and non-man-
aged care the non-managed care.METHODS:Ameta-analysiswas used to estimate
the effectiveness (hospital free years). Cost effectiveness was analyzed in two per-
spectives: the program’s and the payer’s. In the program’s perspective, the litera-
ture was used to estimate the cost. In the payer’s perspective, Thomson Reuter’s
MarketScan datawere used to estimate the cost. RESULTS: It was found that, in the
program’s perspective, a hospital free year’s cost was $8,872.60while in the payer’s
perspective by using managed care; it saved an average of $53,109.22. The propor-
tion of individuals with a hospital free year in managed care and in the usual care
were not found to be statistically significant. CONCLUSIONS: Even though man-
aged care did not have a different hospitalization usage than standard care, it was
found to be cost-effective for the payer.
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OBJECTIVES: Tomodel the costs of thromboprophylaxis following total hip arthro-
plasty (THA) with either low-intensity warfarin, enoxaparin, or fondaparinux.
METHODS: This was a cost-minimization analysis of anticoagulants expected to
have equivalent tolerability and effectiveness. Data were obtained from an HMO’s
joint replacement registry. Patients were included if they had THA between August
2005 and March 2009, continuous enrollment in the 180 days prior to and 90 days
following THA, utilized low-intensity warfarin thromboprophylaxis, and had not
been chronically anticoagulated previously. Patients received warfarin therapy su-
pervised through a pharmacist-run anticoagulation service that included mobile
phlebotomy for INR monitoring. Iterative modeling from the HMO’s perspective
utilized registry data to calculate the costs of thromboprophylaxis with anticoag-
ulants at 2010 AWPminus 35%,monitoring at $50 per phlebotomy, $15 per INR, and
0.1 hour pharmacist time (at $75/hr) per INR. Patient training for any anticoagulant
use was included at 0.25 hr pharmacist time. Duration of therapy was modeled to
a mean of 35 days for injectible (enoxaparin and fondaparinux) thromboprophy-
laxis for which monitoring services would not be required. Sensitivity analyses
included reducing AWPs by 25% prior to discounting and increasing phlebotomy
and INRs to $75 and $25, respectively. RESULTS: 835 THAs for 800 patients were
included. The mean age and duration warfarin therapy were 66 years and 40 days,
respectively, and 62% were females. The base-case thromboprophylaxis cost was
$556 (95% CI$545-$567), $701 (95% CI$693-$709), and $2677 (95% CI$2646-
$2708) for warfarin, enoxaparin, and fondaparinux, respectively. 25% AWP reduc-
tion resulted in thromboprophylaxis costs of $553 (95% CI$542-$564), $564 (95%
CI$558-$571), and $2145 (95% CI$2120-$2171) for warfarin, enoxaparin, and
fondaparinux, respectively. Increasing monitoring costs resulted in thrombopro-
phylaxis cost of $756 (95% CI$740-$771) for warfarin. CONCLUSIONS: Warfarin
thromboprophylaxis had the lowest cost but is sensitive to monitoring costs
whereas injectible thromboprophylaxis is sensitive to drug acquisition costs.
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OBJECTIVES: To conduct a cost-minimization analysis of landiolol for CT diagnosis
of cardiovascular diseases (CVD) suspicious patient with tachycardia in Japan.
METHODS: A decision-tree model was constructed to analyze costs from health-
care payer’s perspective. Drug costs and diagnosis costs, computer tomography
(CT) and coronary angiography (CAG),are adopted to themodel. Landiolol is admin-
istered only to slow the heart rate to take CT image appropriately. Since some trials
proved that there was no difference between landiolol and placebo in terms of
efficacy and safety, we conducted cost-minimization analysis. 22.4% of those who
suspicious for CVD are thought to be take beta-blockers. Success rate for CT scan-
ning for landiolol andplacebo, derived fromdomestic trial data,were 81.4% (96/118,
77.8% - 84.9%) and 54.2% (64/118, 49.7% - 58.8%). Patients who failed to take CT
image were thought to take CAG. The healthcare cost were derived from Japanese
data costs of landiolol, CT imaging, CAG are JPY6,500 (USD79, USD1JPY82.7),
JPY39,100 (USD472) and JPY 105,900 (USD1,279), respectively. Positive rate for CAG,
derived from domestic trial data, were 37.1% (33/89, 32.0% - 42.2%). Various sensi-
tivity analyses, both univariate and probabilistic ones, were conducted. RESULTS:
In the basecase analysis, expected costs per patient for landiolol and placebo were
JPY82,600 (USD998) and JPY85,218 (USD1,029), respectively. In budget impact anal-
ysis, 49,000 patients are eligible for landiolol and it can save JPY 120mil.
(USD1.45mil.) for whole patients. Sensitivity analyses suggested the robustness of
the results. CONCLUSIONS: Landiolol for CT diagnosis of cardiovascular diseases
(CVD) suspicious patient with tachycardia is thought to be cost-saving.
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OBJECTIVES: T2DM is a chronic metabolic disorder characterized by hyperglyce-
mia and associated with significant morbidity. This may be particularly so among
patients with pre-existingmacrovascular conditions (MVC). This study was under-
taken to differentiate healthcare resource utilization between T2DM patients with
and without pre-existing MVC in Europe. METHODS: This is a matched cohort
study based on the Real-Life Effectiveness and Care Patterns of Diabetes Manage-
ment (RECAP-DM) study, a multi-center, observational study with retrospective
medical chart reviews of T2DM patients in eight European countries. Included
patients were aged30 year at time of diagnosis of T2DM and added a SU or a TZD
to failing metformin monotherapy (index date), and had pre-existing (i.e., with
onset date prior to index date) MVC. A control cohort with T2DM but without
pre-existing MVCwas identified using 1:1 propensity scorematching. Logit models
were used to identify the relationship between pre-existingMVC and the likelihood
of ER admission, receivingmedical/surgical procedures, and hospitalization during
the study period. Negative binomial models were used to predict the number of
office visits and length of hospital stay per year attributable to the pre-existing
MVC.RESULTS:Of the 453 eligible patientswith pre-existingMVC (cases), 64%were
male, mean age and time from T2DM diagnosis was 64.5 (9.1) and 6.2 (5.3) years,
respectively. HbA1c prior to the index date was 8.0 (1.2). Relative to controls, pa-
tientswith pre-existingMVCwere significantlymore likely to report ER admissions
(Odds Ratio 3.1; 95%CI 1.8-5.2), receiving medical/surgical procedures (OR 2.72;
95%CI 1.7-4.3), and hospitalizations (OR 2.6; 95%CI 1.7-4.0) after controlling for
other predictors. Similarly, pre-existing MVC incurred 2.9 additional office visits
per year (p0.001) and 0.41 days of hospital stay per year (p0.004).CONCLUSIONS:
This study found that T2DMpatientswith pre-existingMVCweremore likely to use
various types of healthcare resources.
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OBJECTIVES: To determine association between heart failure (HF) and resource
utilization in ST-elevationmyocardial infarction (STEMI) patients treated with Per-
cutaneous Coronary Intervention (PCI).METHODS: Retrospective analysis of I3 In-
Vision Data Mart (2003-08). Adult enrollees (18 years) with primary diagnosis of
STEMI were selected if they were a) treated using PCI procedure and b) had contin-
uous enrollment for at least 6 months prior (baseline) to the STEMI-related index
hospitalization. Enrollees were excluded if they underwent coronary artery bypass
graft during index hospitalization. Pre-existing HF was defined as presence of a
claim comprising relevant HF diagnosis at baseline. New onset HF was defined as
listing of HF as comorbidity in the reimbursement claims for index hospitalization
without supporting evidence for pre-existing HF at baseline. General and general-
ized linear models were used to assess impact of HF (versus no HF) on resource
utilization parameters including length of stay (LOS) and on costs (log-trans-
formed) associated with STEMI-related index hospitalization, respectively. Priori
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